Icosavax (Nasdaq:ICVX) - Cours de l'action, nouvelles et analyse

ICVX Aperçu des actions

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Plus de détails

ICVX analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	0/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Volatilité du cours de l'action au cours des 3 derniers mois

Icosavax, Inc. Concurrents

Vir Biotechnology

NasdaqGS:VIR

US$980.6m

AnaptysBio

NasdaqGS:ANAB

US$677.6m

REGENXBIO

NasdaqGS:RGNX

US$475.1m

MeiraGTx Holdings

NasdaqGS:MGTX

US$463.4m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Icosavax
Historique des cours de bourse
Prix actuel de l'action	US$15.31
Plus haut sur 52 semaines	US$16.11
Plus bas sur 52 semaines	US$4.75
Bêta	1.28
1Variation sur 1 mois	-0.78%
Variation sur 3 mois	50.84%
Variation sur 1 an	68.80%
3Variation sur 3 ans	n/a
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-56.22%

Nouvelles et mises à jour récentes

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Rendement pour les actionnaires

	ICVX	US Biotechs	US Marché
7D	-0.6%	2.5%	2.2%
1Y	68.8%	16.1%	31.6%

Rendement vs Industrie: ICVX a dépassé le secteur US Biotechs qui a rapporté 16.1 % au cours de l'année écoulée.

Rendement vs marché: ICVX a dépassé le marché US qui a rapporté 31.6 % au cours de l'année écoulée.

Volatilité des prix

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement	15.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de ICVX a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ICVX ( 15% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2017	60	Adam Simpson	icosavax.com

Icosavax, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Icosavax se comparent-ils à sa capitalisation boursière ?
ICVX statistiques fondamentales
Capitalisation boursière	US$777.79m
Bénéfices(TTM)	-US$96.71m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-8.0x

Ratio P/E

Le site ICVX est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ICVX compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$70.04m
Marge brute	-US$70.04m
Autres dépenses	US$26.67m
Les revenus	-US$96.71m

Derniers bénéfices déclarés

Sep 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.90
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de ICVX?

Voir les performances historiques et les comparaisons

ICVX Aperçu des actions

Analyse des risques

Icosavax, Inc. Concurrents

NasdaqGS:VIR

US$980.6m

NasdaqGS:ANAB

US$677.6m

NasdaqGS:RGNX

US$475.1m

NasdaqGS:MGTX

US$463.4m

Historique des prix et performances

Nouvelles et mises à jour récentes

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Icosavax, Inc. Résumé des fondamentaux

0.0x

-8.0x